Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Walter Morton who wrote (2606)	2/18/2000 1:25:00 AM
From: Walter Morton	Respond to of 2742

This is what CIST should look like: siliconinvestor.com HYSQ foundation is based on the Interleukin-1 (IL-1) family. Hyseq Announces New Gene Associated with Anti-Inflammatory Activity Hyseq Identifies Second Novel IL-1 Family Member Within a Year SUNNYVALE, CA, May 24, 1999 - Hyseq, Inc. (Nasdaq: HYSQ) today announced a new gene involved in anti-inflammatory activity. This new gene encodes IL-1Hy2 which is a member of the Interleukin-1 (IL-1) family. The announcement follows Hyseq's disclosure in July 1998 of a gene encoding another IL-1 receptor antagonist, IL-1Hy1. These new IL-1 receptor antagonists are believed to be the first members of the IL-1 family to be announced since 1990. IL-1 and tumor necrosis factor (TNF) are cytokines that have been directly linked to the progression of inflammatory diseases including rheumatoid arthritis and chronic inflammatory bowel diseases, such as Crohn's Disease. Hyseq's IL-1Hy1 and IL-1Hy2 are receptor antagonist family members. Receptor antagonists have been identified with activity that block IL-1 cytokines from binding to cell receptors thereby inhibiting inflammation. Hyseq's IL-1 receptor antagonists are potential therapeutic candidates for inhibiting IL-1 binding activities and arresting inflammatory progression. "We believe that Hyseq's two IL-1 receptor antagonists strengthen our growing therapeutic candidate portfolio associated with inflammatory diseases," said Lewis Gruber, President and CEO. "Hyseq's grouping of inflammation-related product candidates and targets, including these new IL-1 family members, is helping us to proceed forward with developing therapeutic and diagnostic products for rheumatoid arthritis and other inflammatory diseases." "In addition to anti-inflammatory applications of our IL-1 receptor antagonists, we are conducting experiments to identify other possible uses for these novel proteins," stated John Ford, Ph.D., Director of Functional Genomics/Immunology. Chronic inflammatory diseases represent a serious worldwide health issue. According to industry sources, rheumatoid arthritis affects approximately 2.3 million people in the U.S., and inflammatory bowel disease an additional half million. For the next four years, annual drug sales for chronic inflammatory diseases may reach over $4 billion. The recent FDA approval of Immunex's drug Enbrel(R), a TNF receptor drug, has validated the efficacy of treatments to block cytokine activity associated with inflammation in rheumatoid arthritis. hyseq.com ________________ I think the stock price was around $3 the last time I posted something about HYSQ to this thread. Now, HYSQ can afford to buy CIST.